

Use red tabs on the side or < and > at the bottom of pages to navigate.
Click on the home icon to return to the front cover.



Voyxact[®]
(sibeprenlimab-szsi)
Injection 400 mg/2 mL

VOYXACT is for adults with a kidney disease called primary IgA nephropathy who are at risk for their disease getting worse.

VOYXACT[®]

Designed to be precise

Block a key driver of IgA nephropathy with the once-every-4-weeks injection that lowers proteinuria.



IgA=immunoglobulin A.
IgAN=IgA nephropathy.

Not an actual patient.

INDICATION

VOYXACT is a prescription medicine used to reduce protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN) who are at risk for their disease getting worse. It is not known if VOYXACT is safe and effective in children.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about VOYXACT?

- **Do not take VOYXACT if you** are allergic to any of the ingredients in VOYXACT.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.

It's important to know that when it comes to proteinuria—the lower the better

Proteinuria, or protein in your urine, is a symptom most people associate with IgA nephropathy. Sometimes proteinuria causes foamy urine, but often there are no signs that a person has it.



New KDIGO[®] Clinical Practice Guideline for the management of IgAN calls for a different way of treating IgA nephropathy and for lower proteinuria goals.

Because of the risks associated with proteinuria, kidney experts updated treatment guidelines for IgA nephropathy. The new approach recommends treating patients if proteinuria levels are 0.5 g/day or higher.

The KDIGO guidelines suggest treating to:



Updated treatment goals are to lower proteinuria to below 0.5 g/day, ideally 0.3 g/day.

KDIGO=Kidney Disease: Improving Global Outcomes.
IgAN=immunoglobulin A nephropathy.
IgA=immunoglobulin A.

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

IgA nephropathy and your immune system activity

The exact cause of IgA nephropathy is unknown. However, it is believed to start outside your kidneys in your immune system. IgA nephropathy is considered to be an immune-driven disease that can affect the kidneys.

How IgA nephropathy is thought to progress.



Your immune system makes Gd-IgA1, which is an abnormal antibody*

These antibodies can form immune complexes that eventually end up in the kidneys



This can cause inflammation and scarring in the kidneys and symptoms like proteinuria

Talk to your nephrologist about your risk and treatment options.

*Antibodies are part of your immune system that usually help fight infections.
Gd-IgA1=galactose-deficient IgA1.

IMPORTANT SAFETY INFORMATION (cont'd)

Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.

How VOYXACT works.

VOYXACT is the first and only FDA-approved treatment that selectively blocks APRIL

APRIL is an immune messenger that helps your body make certain types of antibodies to protect you from infections.

However, in IgA nephropathy, APRIL has been linked to the production of abnormal antibodies called Gd-IgA1.

Over time, these abnormal IgA antibodies can build up in your kidneys, and lead to symptoms like proteinuria.

Blocking APRIL is one way to target the immune system activity of IgA nephropathy—as stated by the KDIGO guidelines.



IgAN=immunoglobulin A nephropathy. APRIL=A Proliferation-Inducing Ligand.
FDA=U.S. Food and Drug Administration. IgA=immunoglobulin A. Gd-IgA1=galactose-deficient IgA1.
KDIGO=Kidney Disease: Improving Global Outcomes.

IMPORTANT SAFETY INFORMATION (cont'd)

Before taking VOYXACT, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection.
- have received or plan to receive therapy that can lower the ability of your immune system to fight infections (immunosuppressive therapy).

Voyxact[®]
(sibeprenlimab-szsi)
Injection 400 mg/2 mL

VOYXACT was designed to precisely block APRIL

Blocking APRIL has been shown to reduce the production of abnormal IgA antibodies (Gd-IgA1), which plays a role in driving IgA nephropathy.

VOYXACT binds to APRIL



IMPORTANT SAFETY INFORMATION (cont'd)

- have recently received or are scheduled to receive an immunization (vaccine). VOYXACT may affect your immune system response to vaccines and increase your risk of infections from live vaccines.
- are pregnant or plan to become pregnant. It is not known if VOYXACT will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if VOYXACT passes into your breast milk or if it will affect your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with VOYXACT.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.

VOYXACT was studied in adults with primary IgA nephropathy who are at risk for their disease getting worse



510 adults with IgA nephropathy were studied in the VISIONARY clinical trial, all with reduced kidney function and protein in their urine.



Adults were randomly assigned into 2 groups—about half received an injection of VOYXACT, and about half received a placebo injection (no active medicine).



Almost all participants (98%) were also receiving the maximum-tolerated dose of blood pressure medications (ACE inhibitors and/or ARBs).




Many (40%) were also taking blood sugar-lowering medications (SGLT2 inhibitors).

IgA=immunoglobulin A. ACE inhibitors=angiotensin-converting enzyme inhibitors.
ARBs=angiotensin receptor blockers. SGLT2 inhibitors=sodium-glucose cotransporter 2 inhibitors.

VOYXACT significantly reduced proteinuria by 50% at 9 months

Change in proteinuria at 9 months of treatment (n = 320).*



The results in this graph are based on an analysis of the first 320 adults in the trial at 9 months. This study is ongoing. These results were consistent across sex, age, race, ethnicity, and geographic region. At the beginning of the trial, participants had a mean uPCR-24h of 1.5 g/g.

The VOYXACT impact: a significant reduction of protein in your urine.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of VOYXACT?

VOYXACT can cause serious side effects, including:

- **immunosuppression and increased risk of infections.** VOYXACT weakens your immune system, which may increase your risk of infections. Your healthcare provider will check you for signs and symptoms of infections before you start and during treatment with VOYXACT. Tell your healthcare provider right away if you develop any signs and symptoms of infection during treatment with VOYXACT, including:


- fever
- chills
- feeling tired
- cough
- flu-like symptoms
- aches and pain
- warm, red, or painful skin

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.



Not an actual patient.

The safety of VOYXACT was evaluated in 510 patients with IgA nephropathy.



Side effects for people taking VOYXACT were similar to those on placebo

Most common side effects of VOYXACT.

	VOYXACT (n = 259)	Placebo (n = 251)
Infections	49%	45%
Upper respiratory infection	15%	14%
Injection-site reactions	24%	23%
Skin redness	13%	12%



Most infections and injection-site reactions were mild to moderate and resolved without pausing or stopping treatment.



Tell your doctor if you develop signs and symptoms of an infection.

IgA=immunoglobulin A.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about VOYXACT?

- Do not take VOYXACT if you are allergic to any of the ingredients in VOYXACT. Stop using VOYXACT and get emergency help if you develop signs and symptoms of an allergic reaction, including:
 - breathing problems
 - swelling of the face, lips, mouth, tongue or throat
 - dizziness or feel lightheaded
 - itching
 - hives
 - skin rash

Please see IMPORTANT SAFETY INFORMATION and full PRESCRIBING INFORMATION, including PATIENT INFORMATION.

How VOYXACT can fit into your care plan

Your care plan is unique to you. It's important to know how VOYXACT can fit into it.

Be sure to continue working with your nephrologist while on VOYXACT. Always reach out to your care team if you have any questions.



VOYXACT is not a steroid; it is a monoclonal antibody (biologic).



VOYXACT can be taken with ACE inhibitors, ARBs, and/or SGLT2 inhibitors.



VOYXACT does not require enrollment in an FDA REMS monitoring program.

IgAN=immunoglobulin A nephropathy. IgA=immunoglobulin A. ACE inhibitors=angiotensin-converting enzyme inhibitors. ARBs=angiotensin receptor blockers. SGLT2 inhibitors=sodium-glucose cotransporter 2 inhibitors. FDA REMS=U.S. Food and Drug Administration Risk Evaluation and Mitigation Strategies.



VOYXACT is delivered right to you.


A convenient treatment

VOYXACT is a **self-administered injection**, dosed **once every 4 weeks**, delivered right to you in a prefilled syringe.



Not an actual patient.

Voyxact[®]
(sibeprenlimab-szsi)
Injection 400 mg/2 mL



VOYXACT is exclusively available through a **specialty pharmacy called PANTHERx[®] Rare**. Once you are prescribed VOYXACT, PANTHERx Rare will call to set up your shipments of VOYXACT, which will be delivered directly to you.

Download the PANTHERx Rare app for delivery coordination and refill requests.



IMPORTANT SAFETY INFORMATION (cont'd)

How should I take VOYXACT?

- Read the detailed "Instructions for Use" that come with VOYXACT for information about how to prepare and inject VOYXACT, and how to properly store and throw away (dispose of) used VOYXACT prefilled syringes.
- Use VOYXACT exactly as your healthcare provider tells you to.
- If you miss a dose of VOYXACT, inject the missed dose as soon as possible. Then take your next dose in 4 weeks.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.

VOYXACT offers ongoing support and savings for eligible patients.



Enroll today for Otsuka Patient Services™



Otsuka Patient Services is a free patient support program for adults who have been prescribed VOYXACT.

When you are enrolled, you will be paired with an Otsuka Care Navigator. Otsuka Care Navigators can provide education and support for getting started on treatment, including information about using the prefilled syringe.

The Otsuka Care Navigator is not a replacement for your nephrologist. Talk to your doctor about any medical questions.

If you have questions about the program or need assistance, call **833-VOYXACT** (869-9228), Monday through Friday, 8 AM-8 PM ET (except holidays).

Savings and support created with you in mind

Prescription savings and coverage for VOYXACT.



The VOYXACT Copay Program may help cover copays and costs for eligible, commercially insured patients who are prescribed VOYXACT. Benefits may apply to copays, coinsurance, and pharmacy deductibles. Maximum annual benefit and other restrictions apply. No copay card is needed. See terms and conditions for more information.



The VOYXACT Bridge Program may provide temporary access to VOYXACT if you experience insurance coverage challenges. Eligible patients with commercial insurance may be able to start VOYXACT immediately while coverage is being determined. See terms and conditions for more information.



Copay Program

Scan this QR code to see terms and conditions or [click here](#).



Bridge Program

Scan this QR code to see terms and conditions or [click here](#).

Or visit VOYXACT.com for full terms and conditions.

Eligible patients may pay as little as \$0 for VOYXACT* or may qualify for temporary access options if insurance coverage challenges arise.†

Otsuka Patient Services™ may call you at the numbers provided for nonmarketing purposes (eg, to help you access and start on VOYXACT). Calls may be autodialed. You may change your preferences at any time by calling 833-VOYXACT (833-869-9228).

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of VOYXACT include: upper respiratory tract infection and skin redness at your injection site.

These are not all of the possible side effects of VOYXACT.

Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.

Not an actual patient.

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT[®] (sibeprenlimab-szsi)

INDICATION

VOYXACT is a prescription medicine used to reduce protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN) who are at risk for their disease getting worse. It is not known if VOYXACT is safe and effective in children.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about VOYXACT?

- **Do not take VOYXACT if you** are allergic to any of the ingredients in VOYXACT. Stop using VOYXACT and get emergency help if you develop signs and symptoms of an allergic reaction, including:
 - breathing problems
 - swelling of the face, lips, mouth, tongue or throat
 - dizziness or feel lightheaded
 - itching
 - hives
 - skin rash

Before taking VOYXACT, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection.
- have received or plan to receive therapy that can lower the ability of your immune system to fight infections (immunosuppressive therapy).
- have recently received or are scheduled to receive an immunization (vaccine). VOYXACT may affect your immune system response to vaccines and increase your risk of infections from live vaccines.
- are pregnant or plan to become pregnant. It is not known if VOYXACT will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if VOYXACT passes into your breast milk or if it will affect your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with VOYXACT.

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take VOYXACT?

- **Read the detailed "Instructions for Use"** that come with VOYXACT for information about how to prepare and inject VOYXACT, and how to properly store and throw away (dispose of) used VOYXACT prefilled syringes.
- Use VOYXACT exactly as your healthcare provider tells you to.
- If you miss a dose of VOYXACT, inject the missed dose as soon as possible. Then take your next dose in 4 weeks.

What are the possible side effects of VOYXACT?


VOYXACT can cause serious side effects, including:

- **immunosuppression and increased risk of infections.** VOYXACT weakens your immune system, which may increase your risk of infections. Your healthcare provider will check you for signs and symptoms of infections before you start and during treatment with VOYXACT. Tell your healthcare provider right away if you develop any signs and symptoms of infection during treatment with VOYXACT, including:
 - fever
 - chills
 - feeling tired
 - cough
 - flu-like symptoms
 - aches and pain
 - warm, red, or painful skin

The most common side effects of VOYXACT include: upper respiratory tract infection and skin redness at your injection site.

These are not all of the possible side effects of VOYXACT.

Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



Take aim at APRIL and lower proteinuria with VOYXACT

SIGNIFICANT REDUCTION IN PROTEINURIA*

50% proteinuria reduction in adults taking VOYXACT at 9 months, compared to a 2% increase in those taking placebo.*

DEMONSTRATED SAFETY

Most common side effects were infections (49% for VOYXACT; 45% for placebo) and injection-site reactions (24% for VOYXACT; 23% for placebo).†

CONVENIENT FOR YOU

A self-administered injection dosed once every 4 weeks.

SAVINGS AND SUPPORT

Eligible patients may pay as little as **\$0 copay**.‡

*Based on the VISIONARY study in 510 adults with IgA nephropathy. Analysis based on the first 320 adults in the trial. Almost all participants (98%) were on the maximum-tolerated dose of ACE inhibitors and/or ARBs, and many (40%) were also taking an SGLT2 inhibitors.

†Safety was studied in 259 adults taking VOYXACT and 251 adults taking placebo.

‡See terms and conditions on page 13.

APRIL=A Proliferation-Inducing Ligand. IgA=immunoglobulin A. ACE inhibitors=angiotensin-converting enzyme inhibitors. ARBs=angiotensin receptor blockers. SGLT2 inhibitors=sodium-glucose cotransporter 2 inhibitors. IgAN=immunoglobulin A nephropathy.

Talk to your nephrologist today to see if VOYXACT is right for you.



To learn more about VOYXACT, visit: www.VOYXACT.com



Scan the QR code to **download the Patient Information or click here**

IMPORTANT SAFETY INFORMATION

What are the possible side effects of VOYXACT?

VOYXACT can cause serious side effects, including:

- **immunosuppression and increased risk of infections.** VOYXACT weakens your immune system, which may increase your risk of infections. Your healthcare provider will check you for signs and symptoms of infections before you start and during treatment with VOYXACT.

Please see **IMPORTANT SAFETY INFORMATION** and full **PRESCRIBING INFORMATION**, including **PATIENT INFORMATION**.



This product information is intended for US consumers only.
VOYXACT is a registered trademark of Otsuka America Pharmaceutical, Inc.
©2026 Otsuka America Pharmaceutical, Inc. All rights reserved.